Javier Crespo
Javier Crespo is an expert in Hepatology at Marqués de Valdecilla University Hospital (Spain). As of October 2026, ScienceLeadR ranks Javier Crespo in the top 1% of experts worldwide for Alcohol-Induced Disorders, MASH and Hepatitis. Javier Crespo has authored 796 publications, the most recent in 2026, and is an investigator in 30 clinical trials, 1 of them ongoing. SLR score: 3,381 (community average: 125). How the SLR is computed.
LeadR Profile
Hepatology
Subspecialties: Gastroenterology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Director of the Research group in Marqués de Valdecilla Research Institute (IDIVAL-HUMV) and Head of the clinical group associated with CIBERehd (GVC16 / EHD / 4), a multidisciplinary and transversal group that includes biologists, biotechnologists, chemists, nurses, and physicians among its components.
Stable research lines in viral hepatitis (more than 25 years, I began with my doctoral thesis I read in 1993) and NASH (I started in 2001 with the publication of an original manuscript in Hepatology), I was a translational research study. I have experience in the management of multi-center projects. At this moment, our group is part of: the core of the Spanish Registry of Metabolic Associated Liver Disease (HEPAMET), the CIBERehd, the European consortium LITMUS for the study of NASH, we participate in more than 30 international clinical trials phase II and III. Moreover, we are running several research projects. I have broad experience in clinical and translational research. I have participated in more than 75 clinical trials phases I to III in HCV, and HBV. I have been granted with several R+D+I projects from public and private calls. I have given more than 100 presentations in national and international courses in liver diseases. I am an author in different guidelines and consensus in gastroenterology and hepatology. I have been a director and co-director in more than 20 national and international courses.
Organizations
Career arc: 1994 - 2026
Number : 796
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 30
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 3
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Evaluate the Efficacy Safety and Tolerability of Fecal Microbiota Transfer for the Treatment of Patients With Nonalcoholic Steatohepatitis NCT05622526 — liver diseases, safety, fecal microbiota transplantation, non-alcoholic fatty liver disease, liver, alcoholics, capsules, therapeutics, fatty liver, transplantation, fatty liver, alcoholic, microbiota | Phase 2 | Not yet recruiting | 2024 |
LeadR Networks
Main global connection map